Myriad Genetics Inc (NASDAQ:MYGN)
| 20.93 Delayed Data As of Dec 02 |  +0.59 / +2.90%Today’s Change | 15.38 Today|||52-Week Range 28.45 | -24.17% Year-to-Date |
Latest MYGN News | Press Releases
| Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound? Dec 02 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 20.34 |
| Today’s open | 19.81 |
| Day’s range | 19.81 - 21.00 |
| Volume | 20,300 |
| Average volume (3 months) | 542,988 |
| Market cap | $1.7B |
Data as of 3:59pm ET, 12/02/2022
Growth & Valuation
| Earnings growth (last year) | +87.01% |
| Earnings growth (this year) | -1,822.22% |
| Earnings growth (next 5 years) | -10.28% |
| Revenue growth (last year) | +8.14% |
| P/E ratio | NM |
| Price/Sales | 3.12 |
| Price/Book | 1.72 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CLDXCelldex Therapeutics... | +0.71 | +1.94% |
| ---- | ||
| VIVOMeridian Bioscience ... | -0.01 | -0.03% |
| VCYTVeracyte Inc | +0.31 | +1.08% |
Data as of 4:00pm ET, 12/02/2022
Financials
| Next reporting date | February 23, 2023 |
| EPS forecast (this quarter) | -$0.15 |
| Annual revenue (last year) | $690.6M |
| Annual profit (last year) | -$27.2M |
| Net profit margin | -3.94% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
